PRTK +34% on reporting Phase 3 study of omadacycline in community-acquired bacterial pneumonia.
DFFN +24% on on being awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications.
ONTX +17% on Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor.
EVOK +16% on positive Type A Meeting with FDA Confirms Acceptability of Pharma’s Proposed Comparative Exposure PK Trial for Gimoti NDA.
CTRV +7% on reporting new insights into the mechanism of action of its hepatitis B virus-optimized cyclophilin inhibitor CRV431.